SEC Filings

Form 424B5
PROTAGONIST THERAPEUTICS, INC filed this Form 424B5 on 10/11/2017
Document Outline
Entire Document (714.8 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - TABLE OF CONTENTS
Page 3 - ABOUT THIS PROSPECTUS SUPPLEMENT
Page 4 - N/A
Page 5 - PROSPECTUS SUPPLEMENT SUMMARY
Page 6 - Janssen Collaboration Agreement
Page 7 - Company Information
Page 8 - THE OFFERING
Page 9 - RISK FACTORS
Page 10 - We are an early clinical-stage biopharmaceutical company with no approved products and no historical
Page 11 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 12 - N/A
Page 13 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 14 - N/A
Page 15 - If Janssen does not elect to continue the development of PTG-200 through an Opt-In Election, our bus
Page 16 - N/A
Page 17 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 18 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 19 - Our research and development strategy for our lead product candidates relies in large part on clinic
Page 20 - Our product candidates may cause undesirable side effects or have other properties impacting safety
Page 21 - We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third par
Page 22 - We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance
Page 23 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 24 - We may not be successful in obtaining or maintaining development and commercialization collaboration
Page 25 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 26 - We have not yet negotiated our agreement with Janssen specifying all of the terms of our Co-Detailin
Page 27 - We currently have no marketing and sales organization. To the extent any of our peptide-based produc
Page 28 - We have focused our limited resources to pursue particular product candidates and indications, and c
Page 29 - If we fail to comply with state and federal healthcare regulatory laws, we could face substantial pe
Page 30 - N/A
Page 31 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 32 - N/A
Page 33 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 34 - We will need to expand the size of our organization, and we may experience difficulties in managing
Page 35 - Our insurance policies are expensive and only protect us from some business risks, which will leave
Page 36 - Our employees, independent contractors, principal investigators, consultants and vendors may engage
Page 37 - We currently conduct, and intend to continue to conduct a substantial portion of the clinical trials
Page 38 - Our headquarters and certain of our data storage facilities are located near known earthquake fault
Page 39 - Risks Related to Our Intellectual Property
Page 40 - N/A
Page 41 - N/A
Page 42 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 43 - The lives of any patents issued as a result of our pending or future patent applications may not be
Page 44 - Third party claims of intellectual property infringement may prevent or delay our drug discovery and
Page 45 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 46 - Because of the expense and uncertainty of litigation, we may not be in a position to enforce our int
Page 47 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 48 - Intellectual property rights do not necessarily address all potential threats to our competitive adv
Page 49 - We may be subject to claims challenging the inventorship or ownership of our issued patents, any pat
Page 50 - We have not yet registered trademarks for a commercial trade name for our product candidates and fai
Page 51 - Risks Related to Ownership of our Common Stock
Page 52 - N/A
Page 53 - Volatility in our share price could subject us to securities class action litigation.
Page 54 - We are obligated to develop and maintain proper and effective internal controls over financial repor
Page 55 - We are an "emerging growth company" and as a result of the reduced disclosure and governance require
Page 56 - If we sell shares of our common stock in future financings, stockholders may experience immediate di
Page 57 - NASDAQ may delist our securities from its exchange, which could limit investors' ability to make tra
Page 58 - Claims for indemnification by our directors and officers may reduce our available funds to satisfy s
Page 59 - Our amended and restated certificate of incorporation provides that the Court of Chancery of the Sta
Page 60 - Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be
Page 61 - FORWARD-LOOKING STATEMENTS
Page 62 - USE OF PROCEEDS
Page 63 - DIVIDEND POLICY
Page 64 - CAPITALIZATION
Page 65 - DILUTION
Page 66 - MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
Page 67 - Distributions on Our Common Stock
Page 68 - Sale, Exchange or Other Disposition of Our Common Stock
Page 69 - Foreign Accounts
Page 70 - UNDERWRITING
Page 71 - Option to Purchase Additional Shares
Page 72 - Electronic Distribution
Page 73 - Selling Restrictions
Page 74 - Notice to Prospective Investors in Canada
Page 75 - LEGAL MATTERS
Page 76 - EXPERTS
Page 77 - WHERE YOU CAN FIND MORE INFORMATION
Page 78 - INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Page 79 - PROSPECTUS
Page 80 - TABLE OF CONTENTS
Page 81 - N/A
Page 82 - SUMMARY
Page 83 - Janssen Collaboration Agreement
Page 84 - Company Information
Page 85 - THE SECURITIES WE MAY OFFER
Page 86 - Preferred Stock.
Page 87 - N/A
Page 88 - RISK FACTORS
Page 89 - N/A
Page 90 - FINANCIAL RATIOS
Page 91 - DESCRIPTION OF CAPITAL STOCK
Page 92 - N/A
Page 93 - Options
Page 94 - Form S-3 registration rights
Page 95 - Staggered Board
Page 96 - Transfer Agent and Registrar
Page 97 - DESCRIPTION OF DEBT SECURITIES
Page 98 - N/A
Page 99 - Conversion or Exchange Rights
Page 100 - N/A
Page 101 - Modification of Indenture; Waiver
Page 102 - Discharge
Page 103 - Information Concerning the Trustee
Page 104 - LEGAL OWNERSHIP OF SECURITIES
Page 105 - Legal Holders
Page 106 - Special Considerations for Global Securities
Page 107 - N/A
Page 108 - PLAN OF DISTRIBUTION
Page 109 - N/A
Page 110 - N/A
Page 111 - LEGAL MATTERS
Page 112 - INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Page 113 - Shares